Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Tumor vascularity" patented technology

Application of metal fullerene monocrystal nanoparticles in preparation of specific tumor vascular disrupting agent

The invention discloses an application of metal fullerene monocrystal nanoparticles in preparation of a tumor vascular disrupting agent. The monocrystal nanoparticles are water-soluble metal fullerene nanoparticles with the surface charged with negative electricity, and have the particle size range of 50-250 nm; the nanomaterial can absorb and convert outside world radiation energy into heat energy, and the volume is expanded sharply when a temperature reaches a phase transition point. During treatment, a tumor-carried living organism is injected and given with the metal fullerene monocrystal nanoparticles; the metal fullerene monocrystal nanoparticles reach a tumor part through blood circulation, and are stranded at tumor pores and defective parts; under the action of the outside world radiation energy, the metal fullerene monocrystal nanoparticles accumulate heat, the temperature rises, and the volume is expanded sharply when the temperature exceeds the phase transformation critical point, so that morphological structures or functions of tumor vascular endothelial cells are changed, and tumor vessels are interdicted so as to make the tumor cells starved to death.
Owner:赤峰福纳康生物技术有限公司 +1

Diphenyl selenide, diphenyl selenoxide, diphenyl selenone compounds and uses thereof

The invention belongs to the technical field of medicine, and relates to diphenyl selenide, diphenyl selenoxide, diphenyl selenone compounds and related compounds thereof, wherein the structure is represented by the following formula. The present invention further provides pharmaceutically acceptable non-toxic salts and hydrates formed by the compounds represented by the structure formula, wherein the pharmaceutically acceptable non-toxic salts comprise salts formed by the derivatives and acids or bases. Pharmacological activity experiment results show that the derivatives have good tumor inhibition activity, and can be used as tumor cell proliferation inhibitors and tumor vascular disrupting agents to be used for antitumor drug preparation.
Owner:SHENYANG PHARMA UNIVERSITY

Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy

The present invention generally relates to methods of preselecting patients for treatment with an anti-VEGF therapy, anti-HIF-1 therapy or anti-thioredoxin therapy. Aspects of the invention combine methods of dynamic contrast enhanced-MRI and diffusion weighted-MRI for the detection of tumor histology. The methodology disclosed herein detects tissue blood volume, tumor vascularity, and abnormal capillary permeability, thereby determining tumor vascularity to determine whether a patient should be administered such therapy.
Owner:PROLX PHARMA +1

Compositions and Methods for Treating Brain Tumors

The present invention relates to methods and medicaments useful for the treatment of brain tumors by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments are provided for reducing tumor cell proliferation and tumor growth, reducing tumor vascularity, inhibiting tumor cell invasion, improving tumor surgical margins and prolonging survival of patients with brain tumors.
Owner:FIBROGEN INC

An ultrasonic prostate cancer diagnosis targeting reagent and a preparing method thereof

The invention relates to an ultrasonic prostate cancer diagnosis targeting reagent and a preparing method thereof. The targeting reagent is perfluoro bromooctane nanoparticles modified by an EpDT3 aptamer. The EpDT3 aptamer is selected from: a) EpDT3-SH that is 5'-GCGACUGGUUACCCGGUCG-(CH2)6-SH-3' and is modified by 2'-fluoropyrimidine; or b) EpDT3-NH2 that is 5'-NH2-spacer-GCGACUGGUUACCCGGUCGinvertedT-3' and is provided with 2'-fluoropyrimidine and 3'-inverted T, wherein the 5'-amino is connected through hexaethylene glycol. The targeting reagent modified by the EpDT3 aptamer can be retained on tumor vascular beds and has excellent targeting property and significantly enhanced developing effects.
Owner:YUEYANG INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL SHANGHAI UNIV OF CHINESE TRADITIONAL MEDICINE

Usage of honokiol in the preparing process of anti tumor angiopoiesis medicine

The invention provides the use of honokiol in the preparing process of anti tumor angiopoiesis medicine with a CAS number of 35354-74-6, the molecular weight being 266.33, the honokiol medicine comprises preparation allowed pharmaceutical excipient or carrier. The dosage form can be intestinal tract or non-intestinal tract combination, and the preparation can be made into liquid preparation, granule, tablet, electuary, capsule, drop pill or injection.
Owner:ZHEJIANG UNIV

Anticancer sustained-release injection containing neovascularization inhibitor

The invention relates to an anti-cancer sustained-release injection containing an angiogenesis inhibitor, which comprises the angiogenesis inhibitor, an amphiphilic block copolymer, a solvent and a certain amount of drug release regulator; wherein, the mixture of the amphiphilic block copolymer and a solvent without organic solvent has the temperature-sensitive gelatinization feature, which is flowable liquid in the environment that is lower than the body temperature and can be automatically converted to the water-insoluble gel that can not flow and be biodegradable for absorption in an endotherm, and the water-insoluble gel can allow the contained angiogenesis inhibitor to have the local sustained release in a tumor and maintain the effective drug concentration for a plurality of weeks to a plurality of months. The sustained-release gel injection can be injected in the tumor or the tumor periphery or be arranged in the postoperative tumor cavity, thus significantly reducing the systemic reaction of the drug and being used for the treatment of the tumors in different stages. The angiogenesis inhibitor is selected from tipifarnib, sirolimus, gefitinib, erlotinib, lapatinib, pelitinib, endostatin, simatinib, dasatinib, avastin, sorafenib, sunitinib, ostwald and so on.
Owner:SHANDONG LANJIN PHARMA +1

Docetaxel drug-loading nanoparticles, preparation method and application thereof

The present invention discloses docetaxel drug-loading nanoparticles, a preparation method and application thereof. The docetaxel drug-loading nanoparticles include nanoparticles, docetaxel wrapped in the nanoparticles, and sulfhydrylation EGF1 protein modified to nanoparticle surface through covalent bond. The nanoparticles are formed from a maleimide-polyethylene glycol- polylactic acid-hydroxy acid polymer. The nanoparticles disclosed by the present invention have good biological targeting, can actively target tumor cells or tumor vascular cells overly expressing tissue factor, and effectively improve the drug concentration at the tumor site, and reduce the toxic and side effects of the drug.
Owner:SUZHOU NANO HEALTH BIOTECH

New preparation for chemotherapy on tumor vascular thrombosis mediated by biological effect of ultrasound

The invention discloses a new preparation for chemotherapy on tumor vascular thrombosis mediated by biological effect of ultrasound. The new preparation comprises a high molecular polymer and docetaxel, wherein the high molecular polymer adopts a polyethylene glycol / poly-(D,L-lactic-CO-glycollic acid) copolymer system, and the copolymer system adopts a polyethylene glycol-poly(lactic-co-glycolic acid)-polyethylene glycol, polyethylene glycol-polylactic acid-polyethylene glycol, poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) or polyethylene glycol / poly(lactic-co-glycolic acid) (PEG / PLGA) graft polymer. The new preparation is characterized in that the mass percent of the docetaxel to the copolymer system is (1:20)-(1:5), and docetaxel carried copolymer nano-micelle is prepared by a direct dissolution method, an emulsified solvent volatilization method or a dialyses method. The new preparation disclosed by the invention is applicable to treatment on many kinds of tumors of mammary gland, thyroid gland, liver, pancreas, kidney, ovary, peritonea and the like.
Owner:FUJIAN MEDICAL UNIV UNION HOSPITAL

Tumor angiogenesis inhibitor jilintong, preparation method and uses thereof

The present invention provides a tumor angiogenesis inhibitor jilintong, a preparation method and uses thereof, and belongs to the technical field of medicine. Specifically the name is 2-hexa alkyl-3-methyl-4(1H)-quinolinone, the chemical formula is C16H21NO, and the tumor angiogenesis inhibitor is named jilintong. The invention further provides a preparation method of the compound, and a tumor angiogenesis inhibition effect of the compound. The jilintong is total synthesis. The compound represented by a formula I provides an inhibition effect for tumor angiogenesis, and has safety so as to provide possibility for development of a new tumor treatment drug.
Owner:CHONGQING UNIV OF TECH

New application of murraya tetramera huang and extract thereof in preparation of medicines

The invention belongs to the technical field of traditional Chinese medicines, in particular relates to new application of a natural plant medicine material and / or extract thereof in medicines for treatment of heart disease, and relates to application of murraya tetramera huang and / or extract thereof in the medicines for treatment of heart disease. The murraya tetramera huang is obtained by crushing any one of leaf, branch, root, flower and fruit of murraya tetramera huang or combination thereof to use as a medicine; the extract is obtained by crushing the murraya tetramera huang, leaching at room temperature, heating for reflux and supercritically extracting, and a solvent used for extraction is a liquid prepared by mutually mixing water and ethanol in any proportion for dissolving, or a liquid prepared by mutually mixing acetone, ether, petroleum ether, chloroform and ethyl acetate in any proportion for dissolving, or liquid CO2. The murraya tetramera huang and / or extract thereof are / is mainly used for comprehensive treatment of coronary heart disease, rheumatic heart disease, hypertensive heart disease, pulmonary heart disease, myocardiopathy, cardiac tumor and vasculopathy. Animal experiments and clinical experiments show that the prepared medicinal preparation has no obvious adverse reactions and toxic and side effects, and is a natural plant medicine capable of providing safe and efficient treatment of heart disease for patients.
Owner:YUNNAN SUNSAIL PHARMA

Eph kinase polypeptide inhibitor and application thereof

The invention belongs to the technical field of biology and specifically discloses an Eph kinase polypeptide inhibitor and application thereof. The polypeptide disclosed by the invention is as shown in formula I. The polypeptide disclosed by the invention has a highly efficient inhibiting effect on Eph kinase, has higher stability and can be used for preparing medicine for treating or preventing Eph kinase abnormal expression related diseases. The polypeptide disclosed by the invention inhibits formation of tumor vasculature through inhibiting abnormal expression of Eph kinase, thereby playing the effect of anti-tumor growth, and the polypeptide can be used for preparing medicine for treating cancer.
Owner:ZHUHAI NOBEL INST OF BIOMEDICINE CO LTD

Methods for Extracting and Quantifying Diagnostic Biomarkers From Ultrasound Microvessel Images

The present disclosure addresses a quantitative analysis of tumor vascularity patterns, with the goal of identifying biomarkers correlated with malignancy. Herein, we identify new types of quantitative ultrasound biomarkers of microvessel morphology that correlate with the state of the disease in question. We propose a novel method to automatically extract quantitative features related to the morphology and distribution of the vascular networks reconstructed from contrast-free ultrasound data. For instance, spatial vascularity pattern, bifurcation angle, Murray's deviation, fractal dimension and closet vessel distance were clearly depicted.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES

1,2-diaryl-2-propenyl-1-ketone compounds and use thereof

The invention belongs to the technical field of medicines, relates to 1,2-diaryl-2-propenyl-1-ketone compounds and use thereof, and particularly relates to the compounds and application thereof as a tumor cell proliferation inhibitor and a tumor vascular disrupting agent in field of preparation of anti-cancer medicines. The compounds of the present invention can be represented by a structural formula in the specification, wherein R1-R8 are defined as the specification.
Owner:SHENYANG PHARMA UNIVERSITY

Traditional Chinese medicine composition for treating anemia caused by gastrointestinal tumors and preparation method thereof

InactiveCN111544522AStrengthen blood intake, hemostasis and nourishing functionPromote wound healingAerosol deliveryOintment deliveryHealed ulcerBletilla striata
The invention relates to a traditional Chinese medicine composition for treating anemia caused by gastrointestinal tumors and a preparation method thereof. According to the traditional Chinese medicine composition, traditional Chinese medicines such as prepared rhizome of rehmannia, radix paeoniae alba, ligusticum wallichii, ginseng, angelica sinensis, astragalus membranaceus, radix actinidiae chinensis, colla corii asini, bletilla striata and carbonized hair are used as raw materials, wherein prepared rhizome of rehmannia and radix paeoniae alba are feminine and soft blood replenishing products, angelica sinensis and ligusticum wallichii are qi-in-blood medicines, ginseng and astragalus membranaceus are added for consolidating and controlling blood, bletilla striata and carbonized hair are added for healing sores and stopping bleeding, colla corii asini adheres to stop bleeding and generate blood and enhance the functions of stopping bleeding and nourishing blood, and radix actinidiaechinensis is added for resisting tumors and ulcer and promoting wound healing. A whole-body internal application method and a local surgical ointment external application method are applied. The traditional Chinese medicine composition disclosed by the invention can be used for treating anemia caused by gastrointestinal tumors by taking the traditional Chinese medicine composition in two ways. The internal administration method can tonify qi, enrich blood, support the healthy energy and consolidate the basis. The ointment is externally applied, is adhered to a local part of a tumor, is adhered to a tumor blood vessel, and is used for treating local ulcers and ulcers of the tumor, healing ulcers and promoting tissue regeneration, controlling blood circulation and stopping bleeding, and specially treating bleeding, so as to treat the symptoms of the tumor.
Owner:马军捷

A dual-target tumor vaccine and its preparation method and application

The invention belongs to the field of biomedicine, and in particular relates to a dual-target tumor vaccine and its preparation method and application. The tumor vaccine of the present invention is composed of tumor vascular endothelial marker GPR124 recombinant eukaryotic expression plasmid and fusion peptide through electrostatic interaction, and GPR124 recombinant eukaryotic expression plasmid is composed of GPR124 gene and eukaryotic expression vector. The dual-target tumor vaccine of the present invention has the following advantages: 1) The tumor vaccine has dual targets, which can simultaneously inhibit tumor angiogenesis and induce tumor cell apoptosis; 2) The vaccine is safe, easy to prepare and purify, has strong immunogenicity, and is easily infected APC uptake; 3) Greatly improve the effectiveness and safety of tumor treatment, and have good application prospects in the field of tumor treatment.
Owner:AFFILIATED YONGCHUAN HOSPITAL OF CHONGQING MEDICAL UNIV

Induction of tumor vascular necrosis utilizing fibroblasts

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.
Owner:FIBROBIOLOGICS

Method for producing antiangiogenesis agent RT-X in colibacillus and application of antiangiogenesis agent RT-X

The invention relates to the technical field of bio-engineering and pharmaceuticals, in particular to a process for producing targeting anti-tumor antiangiogenesis fusion protein RT-X in colibacillus as well as a separation and purification method for the fusion protein RT-X. The fusion protein RT-X is soluble, has biological activity, and comprises RGD and Maspin protein. Through the adoption of the expressed and purified antiangiogenesis agent RT-X with the biological activity, endotheliocyte can be inhibited from migration according to specificity and dose dependence, and an effect for inhibiting angiogenesis is realized in a chicken embryo chorioallantoic membrane animal experiment. The process and the separation and purification method are applicable to research in bio-engineering pharmacy and gene engineering, biochemistry, molecular biology and other fields.
Owner:南通大学技术转移中心有限公司

In-vitro vascular embolism simulation system and method

The invention relates to the technical field of medical equipment, in particular to an in-vitro vascular embolism simulation system and method. Initial pressure signals are provided by pressure sensing equipment, and fluid mechanics states of a tumor vascular network and an embolism agent in a vascular embolism process are simulated through a digital simulation technology. According to the scheme, different tumor vascular networks can be restored, injection of different embolism agents and simulation of the embolism effect can be achieved, enough immediacy and immersion are given to an operator, and the training effect is improved. By injecting different embolism agents, the visitors can feel the viscosity and injection pressure of different embolism agents from the touch sense, so that the visitors can have the feeling of being personally on the scene, and the difference of different embolism agents in the aspects of injection pressure and embolism effect can be evaluated.
Owner:广东广纳安疗科技有限公司

Medicine composition containing both anticancer medicine and its synergist

The medicine composition with both anticancer medicine and its synergist is one kind of slow releasing injection comprising slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material. The solvent is special solvent containing suspending agent. The effective anticancer component is composition of sirolimus, alkylating agent, purine medicine and / or hormone anticarcinogen. The slow releasing supplementary material is selected from polylactic acid, lactic acid copolymer, polifeprosan, etc; the suspending agent is selected from carboxymethyl cellulose, etc and has viscosity of 80cp-3000cp. The medicine composition may be also prepared into slow releasing implant. Using rapamycin and other anticancer medicine can result in synergistic effect.
Owner:SHANDONG LANJIN PHARMA +1

Macrocyclic compounds and uses thereof

The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and / or anti-CAF (Cancer Associated Fibroblasts) activity, orpharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1

Anti-cancer and anti-aging nutritional tablet

The invention discloses an anti-cancer and anti-aging nutritional tablet, which is prepared from the following components in parts by weight: 40 to 60 mg of gallocatechin and acid ester, plant selenium powder, 40 to 60 mg of and sea buckthorn fruit powder, 30 to 50 mg of loach ACE protein peptide, 70 to 90 mg of protein peptide, 30 to 50 mg of donkey-hide gelatin peptide, 70 to 90 mg of sea cucumber peptide, 20 to 40 mg of citric acid, 40 to 60 mg of magnesium stearate, 180 to 220 mg of sorbitol, 40 to 60 mg of resistant dextrin and 80 to 100 mg of whole milk powder. The tablet has the effects of blocking tumor vascularization, resisting cancer and aging, maintaining heart and cerebral vessels, enhancing reproductive function, tonifying kidney and strengthening yang, protecting and nourishing skin, benefiting liver and gallbladder, relieving cough, eliminating phlegm, relieving asthma, improving lung function, promoting tissue regeneration and epithelial tissue healing, preventing diabetes, moistening intestines and nourishing stomach, strengthening tendons and bones, enhancing immunity and the like.
Owner:武汉博识科技有限公司 +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products